A phase 1 study exploring the safety and tolerability of the small molecule Pd-L1 inhibitor, Incb086550, in patients with select advanced tumorss
Le Tourneau, C. Piha-Paul, S. Prenen, H. Delafontaine, B. Pinato, D. Santoro, A. Kristeleit, R. Spencer, K. Gangadhar, T. Burris, H.
Le Tourneau, C.
Piha-Paul, S.
Prenen, H.
Delafontaine, B.
Pinato, D.
Santoro, A.
Kristeleit, R.
Spencer, K.
Gangadhar, T.
Burris, H.
Citations
Altmetric:
Abstract
Authors
Le Tourneau, C.
Piha-Paul, S.
Prenen, H.
Delafontaine, B.
Pinato, D.
Santoro, A.
Kristeleit, R.
Spencer, K.
Gangadhar, T.
Burris, H.
Kotecki, N.
Basu, B.
Graham, Donna
Di Giacomo, A. M.
Sahebjam, S.
Di Nicola, M.
Gomez-Roca, C.
Tomasini, P.
Ascierto, P.
Curigliano, G.
Karasic, T.
Geschwindt, R.
Daniel, J.
Van Cutsem, E.
Piha-Paul, S.
Prenen, H.
Delafontaine, B.
Pinato, D.
Santoro, A.
Kristeleit, R.
Spencer, K.
Gangadhar, T.
Burris, H.
Kotecki, N.
Basu, B.
Graham, Donna
Di Giacomo, A. M.
Sahebjam, S.
Di Nicola, M.
Gomez-Roca, C.
Tomasini, P.
Ascierto, P.
Curigliano, G.
Karasic, T.
Geschwindt, R.
Daniel, J.
Van Cutsem, E.
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Le Tourneau C, Piha-Paul S, Prenen H, Delafontaine B, Pinato D, Santoro A, et al. A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule Pd-L1 Inhibitor, Incb086550, in Patients with Select Advanced Tumors. Journal for immunotherapy of cancer. 2022 Nov;10:A805-A. PubMed PMID: WOS:000919423400730.